BIOCHEMICS & BETH ISRAEL DEACONESS MEDICAL CENTER ANNOUNCE WOUND HEALING RESEARCH COLLABORATION
Danvers, Mass. (April 8, 2008) -- BioChemics, Inc., a company “pioneering transdermal drug delivery,” announced it has entered into a research collaboration with Beth Israel Deaconess Medical Center (BIDMC) to evaluate the wound healing effects of some of the Company’s novel, proprietary formulations in preclinical models. BIDMC is one of the largest, most respected research hospitals in the country. BioChemics is a pharmaceutical company that has developed a novel, transdermal drug delivery system that for the first time may allow almost any drug to be efficiently delivered through the skin. The transdermal technology, called VALE® (Vaso-active Lipid Encapsulated), may allow a substantial portion of the pharmacopeia to be re-engineered, turning oral drugs into transdermals that are safer (no gastro-intestinal problems), cheaper and potentially faster acting (applied directly to the treated area) than oral equivalents.
“The area of wound healing is generating great interest and I look forward to working again with BioChemics, Inc.,” said Dr. Aris Veves, Joslin-Beth Israel Deaconess Foot Center, Associate Professor in Surgery, Harvard Medical School.
Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School, and consistently ranks in the top four in National Institutes of Health funding among independent hospitals nationwide. BIDMC is clinically affiliated with the Joslin Diabetes Center and is a research partner of Dana-Farber/Harvard Cancer Care Center. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.harvard.edu.
Dr. Aris Veves, Research Director, Joslin-Beth Israel Deaconess Foot Center, Associate Professor in Surgery , Harvard Medical School
Dr. Veves’ areas of expertise include diabetic neuropathy, diabetic foot problems, and vascular reactivity. His main academic interest is the vascular reactivity of micro- and macrocirculation and in the past two years, he has served as Director of the Microcirculation Lab, which tests microvasculature in a non-invasive way. He is also interested in the etiology of diabetic foot problems and the pathophysiology of wound healing in diabetes. Other interests include the effect of c-nociceptive fiber dysfunction of wound healing and the diabetes-related impairment of angiogenesis.
Dr. Aristidis Veves received his M.D. from the Medical School, Aristotelion / University of Thessaloniki (Greece), his M.Sc. from the Faculty of Medicine, University of Manchester (U.K.), and his D.Sc. from Athens Medical School (Greece). Dr. Veves did his internship in General Medicine at Athens Naval Hospital (Greece), and completed his residency in General Medicine at Tsaggari General District Hospital (Athens, Greece). He then served as Hon. Senior House Officer in the University Department of Medicine, Diabetes and Endocrinology at Manchester Royal Infirmary (U.K.). Following this, he was a Clinical Research Fellow in the same department. Most recently, he was a Research Fellow at Deaconess – Joslin Foot Center, Deaconess Hospital (Boston, MA).
About BioChemics, Inc.
VALE® is a registered trademark of BioChemics, Inc.
Contact: BioChemics, Inc.,